Selecta Licenses LMB-100 for Combination Tests with SVP-Rapamycin in Mesothelioma, Other Cancers
News
Selecta Biosciences has licensed to use and test the experimental anti-cancer drug LMB-100 from the Center for Cancer Research (CCR) at the National Cancer Institute (NCI). The agreement promotes additional development ... Read more